Follow us on:

Advanced Oncotherapy the end goal is very much in sight (Analyst Interview)

Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk. Martin explains what’s been happening with the company lately, the potential advantages of LIGHT, how close we are to the first system, how AVO is funding all the work and what investors and potential investors can look forward to over the coming months.

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

Its focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient’s healthy tissues.

You might also enjoy reading NB Private Equity Partners, the Unique Value of Co-Investment in Private Equity (VIDEO)

Find more news, interviews, share price & company profile here for:

Hardman & Co

Share this interview

Other Interviews

ICG Enterprise Trust practical assessment of defensive growth strategy (VIDEO) July 19, 2023
Apax Global Alpha Capital Markets Day: value added by the manager (VIDEO) July 17, 2023
NB Private Equity Partners PE co-investment niche to generate superior returns (VIDEO) July 11, 2023
H&T Group – Why is pawnbroking so attractive at the moment? (VIDEO) June 22, 2023
ICG Enterprise FY’23 results proving the value of a defensive growth strategy (VIDEO) June 19, 2023
Chesnara plc Strong cash generation through tough markets (VIDEO) April 28, 2023
Arbuthnot Banking Group core and new franchises growth in profits and loans (VIDEO) April 25, 2023
Why pick Fidelity China Special Situations if you want to invest in China? (VIDEO) April 4, 2023
Oakley Capital Investments 2022 Results: EBITDA Growth Drives NAV Appreciation (VIDEO) March 29, 2023
H&T Group Unique opportunities for strong, profitable growth (VIDEO) March 27, 2023

More News

Advanced Oncotherapy Update on Bracknor financing April 28, 2017
Advanced Oncotherapy Plc Investor presentation and Update March 7, 2017
Advanced Oncotherapy Plc Start work on Harley Street site end of Q1 February 24, 2017
Advanced Oncotherapy plc £26m flexible, staged finance agreement agreed with Dubai investment firm February 22, 2017
Advanced Oncotherapy Plc Investor presentation 6th March 2017 February 16, 2017
Advanced Oncotherapy Plc bring expert clinical knowledge with the appointment of Dr Nick Plowman February 9, 2017
Advanced Oncotherapy Dr Nick Plowman becomes significant shareholder February 8, 2017
Advanced Oncotherapy plc appoint Professor Steve Myers & Mr Hans von Celsing as Non-Executive Directors January 26, 2017
Advanced Oncotherapy Plc Non-dilutive financing plan update January 23, 2017

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.